Evidence map›Paper›PMID 26759040›Full record

ArticleKidney international2016

Bone strength: more than just bone density.

Susan M Ott

Open access · bronzeAbstract readComment
PubMed Publisher
In one paragraph

Article in Kidney international, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
3.3field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 39 citations in OpenAlex.

  1. Observational
  2. Article
  3. Review
  4. Observational
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Menopause Is More Than Just Loss of Fertility.The Public policy and aging report · 2023
    Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Bone density, microarchitecture, and material strength in chronic kidney disease patients at the time of kidney transplantation.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2017
    Article
  20. Renal Osteodystrophy-Time for Common Nomenclature.Current osteoporosis reports · 2017
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Susan M OttDepartment of Medicine, University of Washington, Seattle, Washington, USA. Electronic address: smott@uw.edu.
University of Washington · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The following bone density measurements have limited utility in determining bone strength because they do not include bone quality: microarchitecture, mineralization, ability to repair damage, collagen structure, crystal size, or marrow composition. Patients with kidney disease have poor bone quality. Newman et al. now describe beneficial effects with raloxifene in an animal model of progressive kidney disease. These biomechanical measurements will be important in the development of medications to decrease fractures in patients.

Indexed as

Bone DensityAnimalsBone and BonesBone Density Conservation AgentsHumansOsteoporosisRaloxifene HydrochlorideBone Density Conservation AgentsRaloxifene Hydrochloride

Identifiers

PMID26759040
OpenAlexW2228646576

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.